Cramer on Johnson & Johnson: Cramer remained bullish on Johnson & Johnson
JNJ
, despite a pause on the company’s COVID-19 vaccine trial.
“It’s a pause, not a hold," said Cramer. He expects to get results from the pause over the next four to five days.
Cramer mentioned strong organic growth and good growth for the company’s medical devices.
He called Johnson & Johnson a “good stock right now" and think investors will regret selling the stock.
benzinga
JNJ
, despite a pause on the company’s COVID-19 vaccine trial.
“It’s a pause, not a hold," said Cramer. He expects to get results from the pause over the next four to five days.
Cramer mentioned strong organic growth and good growth for the company’s medical devices.
He called Johnson & Johnson a “good stock right now" and think investors will regret selling the stock.
benzinga